Increased urinary losses of carnitine during ifosfamide chemotherapy.
Chloroacetaldehyde and thiodiglycolic acid, two metabolites of ifosfamide, interfere with mitochondrial function and may sequester carnitine. Urinary excretion of carnitine was measured in five patients before and during a continuous infusion of ifosfamide over 5 days at a dose of 2.8-3.2 g/m2 per day. The excretion of free and total carnitine increased from 85+/-53 to 2697+/-1393 micromol/day on the 1st day of chemotherapy and then gradually decreased. The average loss of carnitine during a chemotherapy cycle amounted to 8.5 mmol. The formation and excretion of esters of carnitine and metabolites of ifosfamide and/or a decreased renal tubular reabsorption could account for this marked loss, which might lead to symptomatic carnitine deficiency after several chemotherapy cycles.
Department of Clinical Pharmacology, University of Bern, Switzerland.
N P
NP
Marthaler
T
T
Visarius
A
A
Küpfer
B H
BH
Lauterburg
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D002331:Carnitine / Q000652:urine*; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged
D018906:Antineoplastic Agents, Alkylating; D002331:Carnitine; D007069:Ifosfamide